Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amlodipine + losartan potassium + hydrochlorothiazide is a fixed-dose combination medication used primarily for the treatment of hypertension (high blood pressure). It combines three antihypertensive agents with complementary mechanisms: - **Amlodipine** is a calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle. This action relaxes blood vessels and lowers blood pressure. - **Losartan potassium** is an angiotensin II receptor blocker (ARB) that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking its binding to the AT1 receptor in many tissues. This leads to vasodilation and reduced blood pressure. - **Hydrochlorothiazide** is a thiazide diuretic that increases excretion of sodium and water by inhibiting sodium reabsorption in the distal tubules. This reduces plasma volume and decreases blood pressure. The combination provides additive antihypertensive effects through these distinct pathways. Lowering high blood pressure helps prevent strokes, heart attacks, heart failure, kidney failure, and other complications associated with chronic hypertension[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amlodipine + losartan potassium + hydrochlorothiazide.